Background {#s1}
==========

Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy caused by the pathological accumulation of aberrant prion protein (PrP), neuronal death and spongiform change throughout the brain. With an incidence of approximately 1 in 1 000 000, CJD is a rare but fatal condition. CJD has several possible aetiologies: sporadic (sCJD), familial, iatrogenic (iCJD) and variant CJD (vCJD) in which PrP is transmitted to humans across a species barrier. Different aetiologies of CJD present with different clinical and pathological phenotypes. vCJD typically has an earlier age of onset of approximately 26 years,[@R1]compared with sCJD in which only 4.5% of cases present before the age of 40 years. vCJD typically presents with behavioural and psychiatric symptoms followed later by sensory abnormalities, ataxia and dementia. In contrast, iCJD and sCJD are more likely to show a clinically and pathologically heterogeneous picture. Histologically, florid plaques are seen in vCJD, whereas iCJD and sCJD can show varying severities of PrP deposition, including 'kuru-like' plaques. Here we present a case of sCJD with an atypical presentation with parkinsonism, prominent early dementia and death within 3 years of symptom onset. We have been able to perform a detailed neuropathological investigation, and have identified this case as a rare subtype of this rare disease, with an unusually long disease course.

Case presentation {#s2}
=================

A 64-year-old male patient who had previously been investigated for tension headaches presented with a 2-year history of memory impairment, reduced attention and alertness. These were present alongside an 'alien' left arm with numbness and cramps, mild resting and postural tremor, bradykinesia, increased tone and reduced arm swing, more so on the left. He exhibited amnesia for recent events, executive dysfunction, anomia and apractagnosia. This clinical syndrome met the consensus diagnostic criteria for probable sporadic corticobasal degeneration (CBD), given the asymmetric limb bradykinesia and rigidity, multiple higher cortical signs.[@R2] He retained only partial insight into his condition. He did not smoke and took minimal alcohol. The family history was negative for neurological disease.

Investigations {#s3}
==============

Initial Mini Mental State Examination yielded a score of 28/30 with deficits in recall and visuospatial function. Addenbrooke's cognitive examination yielded a score of 74/100 with prominent deficits in memory, fluency, language and visuospatial domains. There was no evidence of rapid eye movement-sleep behaviour disorder, visual hallucinations or fluctuating cognition, which are core features for the diagnosis of dementia with Lewy bodies (DLB).[@R3] DaTScan revealed heterogeneous uptake bilaterally in the basal ganglia ([figure 1A](#F1){ref-type="fig"}) more so on the right than left, which does not suggest Parkinson's disease. During investigation for tension headaches 1 year previously, an MRI scan was performed which showed T2-weighted hyperintensities in the basal ganglia and cortical white matter ([figure 1B,C](#F1){ref-type="fig"}), but an otherwise normal cerebrum ([figure 1D](#F1){ref-type="fig"}). By 2-years postpresentation, the MRI showed significant cortical and hippocampal atrophy on MRI ([figure 1E](#F1){ref-type="fig"}), cortical ribboning and thalamic high signal on diffusion-weighted imaging ([figure 1F](#F1){ref-type="fig"}).

![Neuroimaging findings. (A) DaTscan of basal ganglia 1 year after onset showing heterogeneous but atypical reduced uptake. (B) T2-weighted MRI showing hyperintensities in the basal ganglia (C) T2-weighted MRI showing hyperintensities in cerebral white matter at 1 year before onset. (D) Coronal MRI from 1 year before onset (background of chronic headaches). (E) Coronal MRI from 1 year after onset showing significant cortical and hippocampal atrophy and ventricular dilatation. (F) Diffusion-weighted MRI from 1 year after onset showing hyperintense cortical ribboning in the frontal, parietal and occipital cortices, insula and thalamus.](bcr-2018-228305f01){#F1}

Differential diagnosis {#s4}
======================

An initial working differential diagnosis of CBD or DLB, despite a lack of DLB core clinical features,[@R3] was made.

Treatment {#s5}
=========

The patient was prescribed 10 mg daily of the cholinesterase inhibitor donepezil.

Outcome and follow-up {#s6}
=====================

By the next visit, at 3 months after presentation, significant deficits in global cognition were noted, despite cholinesterase inhibition. At 6 months, the patient had developed marked fatigue, word-finding difficulties and a stammer which severely impeded speech. Significant deficits in cognition were also present: a Rowland University Dementia Assessment Scale was applied, yielding a score of 9/30 with marked deficits in praxis, visuoconstructional function, judgement, memory and language. Rivastigmine was prescribed in place of donepezil.

By 1.5 years after initial examination, his parkinsonism had worsened considerably with increased tremor and rigidity of the left hand, multiple falls, bilateral apraxia and bradykinesia of the hands (worse on the left), a fixed flexion deformity of the left hand. Reduced upgaze was noted on examination, raising the possibility of a diagnosis of an atypical parkinsonian syndrome. An initial dose of levodopa was prescribed in the form of 62.5 mg of levodopa, taken to times per day. However, there was no clear response to levodopa.

By 2 years postpresentation, the patient had become wheelchair-bound, was experiencing rest tremors bilaterally, postural instability, significant axial and limb rigidity and akinetic mutism. Neuroimaging showed significant cortical and hippocampal atrophy, ventricular dilatation, diffusion-weighted cortical 'ribboning' in the frontal and occipital cortices and basal ganglia hyperintensities. The patient passed away soon after due to causes secondary to parkinsonism. His brain was collected by the Parkinson's UK Tissue Bank at Imperial College London.

Gross macroscopic examination revealed cortical and cerebellar atrophy, dilatation of the ventricular system but a well-pigmented substantia nigra.

Microscopically, prominent microvacuolation ([figure 2A-F](#F2){ref-type="fig"}) was found in the cortex, striatum hippocampus, cerebellum and thalamus. Immunostaining for α-synuclein revealed no immunopositive structures in any region. There were frequent amyloid-β plaques in the frontal, temporal, entorhinal and transentorhinal cortices and striatum. Immunostaining for hyperphosphorylated tau revealed moderate neurofibrillary tangle and neuropil thread pathology in the entorhinal and transentorhinal cortices only. A diagnosis of spongiform encephalopathy was made and the case was sent to the National CJD Research and Surveillance Unit in Edinburgh for further neuropathological assessment.

![Neuropathology slides for the substantia nigra, caudate, cerebellum, hippocampus and cingulate gyrus. Top row: H&E stained slides, (A) substantia nigra, (B) caudate, (C) cerebellum, (D) hippocampus, (E) cingulate gyrus, (F) frontal cortex. Bottom row: slides immunostained with antibodies against prion protein, (G) substantia nigra, (H) caudate, (I) cerebellum, (J) hippocampus, (K) cingulate gyrus, (L) frontal cortex. Images taken with ImageProPlus V.7.0 at ×400 magnification (×1000 for F & L to show intense vacuolation in cortex). Inset are ×2000 magnification images of pathology from caudate, cerebellum and cingulate gyrus.](bcr-2018-228305f02){#F2}

Immunostaining for PrP ([figure 2G-L](#F2){ref-type="fig"}) revealed widespread deposition in an intense perivacuolar pattern, without kuru-type plaques. Severe deposition was found throughout the cortex and basal ganglia, while the hippocampus, substantia nigra and cerebellum were relatively spared.

Western blot analysis confirmed a protease-resistant PrP with regional variation of the PrP isoforms present. In the frontal cortex, the type 2A isoform was detected with a low molecular weight (LMWt) band. The type 1A isoform was detected in the cerebellum, again with a LMWt band.

Analysis of the codon 129 polymorphism in the PrP gene showed that this patient was a methionine/valine heterozygote. Full sequence analysis of the PrP gene found no pathogenic mutations.

Discussion {#s7}
==========

We report a case, clinically thought to be CBD, but at postmortem was found to be sCJD. This was a diagnosis that was not considered due to a long disease course, meaning that no cerebrospinal fluid (CSF) analysis for 14-3-3 protein was performed. However, the specificity of this test has been questioned. In one study, a false positive rate of approximately 30% was found in a population with 14-3-3 protein detected in the CSF who also met diagnostic criteria for probable sCJD.[@R4] Only 59% of this population were found to have sCJD and, interestingly, none were found to have CBD pathology.[@R4] A diagnostic test such real-time quaking induced conversion (RT-QuIC), with a similar sensitivity to 14-3-3 CSF analysis but a specificity rate of 98%--100%[@R5] would have been a more useful test for the diagnosis of CJD before the patient's death. Nonetheless, histological, immunohistochemical and biochemical analysis of this case confirms a diagnosis of sCJD of the met/val heterozygote PrP strain 2 (MV2) subtype classification. sCJD MV2 can be further subdivided as being predominantly cortical (C), as having kuru-like plaques (K), or a mixture (K+C). The pathology in this case was predominantly of a cortical type with absence of kuru-type plaque pathology, allowing a further subclassification into the MV2C (cortical) histotype: a relatively rare form of a rare disease.

While the clinical phenotype is variable, sCJD should always be considered in any patient with a rapidly progressing dementia. However, as this case shows, sCJD should also be considered in cases with slower progression, particularly when the symptoms are atypical for more common disorders such as CBD or DLB. sCJD MV2C has been described as having a longer clinical duration, and typically presents with ataxia, but can present with extrapyramidal symptoms such as parkinsonism. The present case showed an atypical parkinsonian syndrome with alien limb phenomenon, suggestive of a corticobasal syndrome. Corticobasal syndrome was previously reported in a case of CJD by Zhang *et al*, but this lacked pathological workup of the case.[@R7] Similarly, Erdal *et al* found corticobasal symptoms in a case of CJD confirmed by CSF biomarker analysis.[@R8] Lee and colleagues sought to characterise the clinical syndrome in cases of sCJD presenting with CBS.[@R9] Their data showed that the clinical syndrome is highly variable between cases. However, they found that the clinical features most prevalent in sCJD-CBS cases were alien limb phenomena, limb apraxia, rigidity, sensory loss, myoclonus and cognitive impairment, all of which were present in the case we have presented. Marin *et al* reported a case of suspected CJD causing a clinical syndrome similar to DLB,[@R10] however this report also lacked pathological confirmation of the diagnosis. In a previous cohort study, 46% of sCJD patients met clinical diagnostic criteria for DLB.[@R11] CJD is one of the main differential diagnoses for DLB. Because cases with the MV2C subtype have a slower disease onset and progression than typical sCJD, which is usually fatal within 6--12 months, they can frequently be misdiagnosed.

There are multiple diagnostic neuroimaging findings for sCJD, some of which were present in this case and are atypical for both CBD and DLB. These include diffuse-weighted imaging (DWI) findings of high signal in the cortex and basal ganglia. Further to this, specific polymorphisms of sCJD show different patterns of DWI lesions, whereby cases that are PrP codon 129 homozygotes generally show focal, and heterozygotes more diffuse abnormalities.[@R12] In this case, diffuse cortical 'ribboning' was observed, and hyperintensity in the thalamus (a finding present in at least 43% of heterozygous sCJD).[@R12]

Our clinical diagnostic criteria for neurodegenerative disorders more generally lack specificity, with a number of comorbid pathologies being notes in clinicopathological studies of clinically defined conditions such as Alzheimer's disease, where α-synuclein, tar DNA binding protein-43 and vascular pathology are found to significantly contribute to the neurodegeneration.[@R13] Though this case demonstrated the clinical diagnostic criteria for probable CBD, it also exhibited signs suggestive of probable CJD by University of California San Francisco criteria[@R16]: dementia, extrapyramidal features, higher cortical signs (such as apractagnosia) and akinetic mutism with typical neuroimaging findings. There is a need in the wider field to address the high error rate in the diagnostic criteria for neurodegenerative diseases such as sCJD or CBD.

###### Learning points

-   Sporadic Creutzfeldt-Jakob disease (sCJD) is an important differential diagnosis in cases of atypical neurodegenerative syndromes.

-   Diffusion-weighted imaging alongside other imaging and cerebrospinal fluid real-time quaking induced conversion can aid diagnosis in atypical cases.

-   sCJD should be considered in all cases with severe and rapid cerebral atrophy demonstrated on MRI.
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